Novo wins EU recommendation for two-in-one diabetes drug

LONDON (Reuters) - A Novo Nordisk drug combining its long-acting insulin degludec with its type 2 diabetes treatment Victoza has been recommended for approval in Europe, in an important boost for the Danish company.

Source: Reuters: Health - July 25, 2014 Category: Consumer Health News Tags: healthNews Source Type: news